{"id":59434,"date":"2024-05-28T04:04:32","date_gmt":"2024-05-28T02:04:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/"},"modified":"2024-05-28T04:04:32","modified_gmt":"2024-05-28T02:04:32","slug":"revolka-signed-master-service-agreement-with-daiichi-sankyo","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/","title":{"rendered":"RevolKa Signed Master Service Agreement with Daiichi Sankyo"},"content":{"rendered":"
\n

\nRevolKa will create highly functional proteins by using AI-driven platform<\/i><\/p>\n

TOKYO–(BUSINESS WIRE)–RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Norio Hamamatsu, President and CEO) signed a master service agreement with Daiichi Sankyo Co., Ltd. (Hiroyuki Okuzawa, President and COO). RevolKa will create and deliver highly functional proteins, in collaboration with Daiichi Sankyo Co., Ltd. by using its proprietary protein engineering platform technology, called ai<\/i>Protein\u00ae: a robust directed protein evolution technology integrated with artificial intelligence (AI). Details of this agreement and financial terms were not disclosed.<\/p>\n

<\/a>
<\/a><\/p>\n

\nAbout ai<\/i>Protein<\/b>\u00ae Technology<\/b><\/p>\n

\nRevolKa\u2019s proprietary technology, ai<\/i>Protein\u00ae is an AI-assisted directed evolution of proteins. Naturally occurring protein is a linear polymer of amino acids and their derivatives, which folds into a tertial structure through internal complex atomic interactions to show biological function. Proteins have evolved to biologically functional molecules over hundreds of millions of years. The relationship between protein sequence, structure, and function in those highly functioned molecules remains poorly understood to rationally design a protein sequence for a particular function. Our AI engine is trained with sequence-function relationship data to statistically predict sequences for an evolved protein function. Furthermore, ai<\/i>Protein\u00ae can evolve more than two functions simultaneously. This technology is a powerful and cost-effective tool for the creation of novel and highly-optimized proteins for pharmaceutical and industrial uses.<\/p>\n

\nAbout RevolKa Ltd.<\/b><\/p>\n

\nRevolKa is a venture-backed biotechnology company founded in April 2021 by academic and industry experts in biotechnology and artificial intelligence. Our mission is to create novel proteins useful for therapeutics and industries by using our own proprietary technology platform, ai<\/i>Protein\u00ae to contribute to human well-being. The name “RevolKa” is derived from the Latin word for evolution, “evolutio\u201d and the Ainu (an indigenous Japanese people) word for raise, \u201creska\u201d. RevolKa\u2019s headquarters are located in Tokyo, Japan with laboratories located in Sendai. The company\u2019s investors include D3 LLC, DEEPCORE Inc., Tohoku University Venture Partners, and SBI investment Co., Ltd.. For more information, visit https:\/\/www.revolka.com\/en\/<\/a><\/b>.<\/p>\n

\nAbout Daiichi Sankyo Co., Ltd.<\/b><\/p>\n

\nFor more information, visit https:\/\/www.daiichisankyo.com\/<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nRevolKa Ltd.
\n
Ayumi Iwase
\n
Email: info@revolka.co.jp<\/a>
TEL: +81-3-5990-9858<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

RevolKa will create highly functional proteins by using AI-driven platform TOKYO–(BUSINESS WIRE)–RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Norio Hamamatsu, President and CEO) signed a master service agreement with Daiichi Sankyo Co., Ltd. (Hiroyuki Okuzawa, President and COO). RevolKa will create and deliver highly functional proteins, in collaboration with … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59434","6":"format-standard","7":"category-industry"},"yoast_head":"\nRevolKa Signed Master Service Agreement with Daiichi Sankyo - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RevolKa Signed Master Service Agreement with Daiichi Sankyo - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"RevolKa will create highly functional proteins by using AI-driven platform TOKYO–(BUSINESS WIRE)–RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Norio Hamamatsu, President and CEO) signed a master service agreement with Daiichi Sankyo Co., Ltd. (Hiroyuki Okuzawa, President and COO). RevolKa will create and deliver highly functional proteins, in collaboration with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-28T02:04:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240527930585\/en\/2138541\/22\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-signed-master-service-agreement-with-daiichi-sankyo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-signed-master-service-agreement-with-daiichi-sankyo\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"RevolKa Signed Master Service Agreement with Daiichi Sankyo\",\"datePublished\":\"2024-05-28T02:04:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-signed-master-service-agreement-with-daiichi-sankyo\\\/\"},\"wordCount\":367,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-signed-master-service-agreement-with-daiichi-sankyo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240527930585\\\/en\\\/2138541\\\/22\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-signed-master-service-agreement-with-daiichi-sankyo\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-signed-master-service-agreement-with-daiichi-sankyo\\\/\",\"name\":\"RevolKa Signed Master Service Agreement with Daiichi Sankyo - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-signed-master-service-agreement-with-daiichi-sankyo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-signed-master-service-agreement-with-daiichi-sankyo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240527930585\\\/en\\\/2138541\\\/22\\\/logo.jpg\",\"datePublished\":\"2024-05-28T02:04:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-signed-master-service-agreement-with-daiichi-sankyo\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-signed-master-service-agreement-with-daiichi-sankyo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-signed-master-service-agreement-with-daiichi-sankyo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240527930585\\\/en\\\/2138541\\\/22\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240527930585\\\/en\\\/2138541\\\/22\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revolka-signed-master-service-agreement-with-daiichi-sankyo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RevolKa Signed Master Service Agreement with Daiichi Sankyo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RevolKa Signed Master Service Agreement with Daiichi Sankyo - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/","og_locale":"en_US","og_type":"article","og_title":"RevolKa Signed Master Service Agreement with Daiichi Sankyo - Pharma Trend","og_description":"RevolKa will create highly functional proteins by using AI-driven platform TOKYO–(BUSINESS WIRE)–RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Norio Hamamatsu, President and CEO) signed a master service agreement with Daiichi Sankyo Co., Ltd. (Hiroyuki Okuzawa, President and COO). RevolKa will create and deliver highly functional proteins, in collaboration with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/","og_site_name":"Pharma Trend","article_published_time":"2024-05-28T02:04:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240527930585\/en\/2138541\/22\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"RevolKa Signed Master Service Agreement with Daiichi Sankyo","datePublished":"2024-05-28T02:04:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/"},"wordCount":367,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240527930585\/en\/2138541\/22\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/","url":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/","name":"RevolKa Signed Master Service Agreement with Daiichi Sankyo - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240527930585\/en\/2138541\/22\/logo.jpg","datePublished":"2024-05-28T02:04:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240527930585\/en\/2138541\/22\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240527930585\/en\/2138541\/22\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/revolka-signed-master-service-agreement-with-daiichi-sankyo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"RevolKa Signed Master Service Agreement with Daiichi Sankyo"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59434"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59434\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}